Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04444869 · ClinicalTrials.gov registry record · Phase 2
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
A Phase 2 study of Oropharynx Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT04444869: Recruiting Phase 2 study of Oropharynx Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by University of Missouri-Columbia.
NCT04444869 is a Phase 2 study of Oropharynx Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 28 participants, below the 131-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04444869, a Phase 2 study of Oropharynx Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will explore giving standard dose chemotherapy and radiation therapy to sites of disease including all lymph nodes involved with HPV-positive oropharyngeal cancer, but administer lower doses of radiation therapy to the lymph nodes that are not known to be involved with cancer. By doing so, it is hypothesized that there will be equally good long term loco-regional and distant disease control but will reduced long term treatment side effects and improved quality of life in persons living well beyond their cancer treatment.
Conditions Studied
Interventions
- DRUG Cisplatin injection
Study Locations (1)
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT04444869 shows while recruiting
NCT04444869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 131-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (79% lower).
The record links to 4 conditions, with Oropharynx Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin injection is the first listed.
NCT04444869 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04444869 about?
NCT04444869 is a clinical study titled "Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer". This trial will explore giving standard dose chemotherapy and radiation therapy to sites of disease including all lymph nodes involved with HPV-positive oropharyngeal cancer, but administer lower doses of radiation therapy to the lymph nodes that are not known to be involved with cancer. By doing so...
What is the current status of trial NCT04444869?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2020-09-28. Estimated completion is 2026-06.
What conditions does trial NCT04444869 study?
This clinical trial studies the following conditions: Oropharynx Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cancer of the Head and Neck, Throat Carcinoma.
What interventions are being tested in trial NCT04444869?
The interventions under investigation include: Cisplatin injection (DRUG).
Who is sponsoring clinical trial NCT04444869?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04444869 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04444869's enrollment target sits among peer trials
28 22nd of 26 higher than 5 of 26 other Oropharynx Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharynx Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
RECRUITING · Phase 2
-
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI